Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05950711 · ClinicalTrials.gov registry record · Phase 4

Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study

A Phase 4 study of Major Depressive Disorder, sponsored by Ohio State University.

Active
Registry status
Phase 4
Development phase
21
Enrollment target
1
Study location

NCT05950711: Active Phase 4 study of Major Depressive Disorder, sponsored by Ohio State University.

NCT05950711 is a Phase 4 study of Major Depressive Disorder that is active but no longer recruiting, run by Ohio State University. The registered enrollment target is 21 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05950711, a Phase 4 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by Ohio State University.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.

Primary Outcome

Response defined a ≥50% reduction in depressive symptoms as measured of standardized measures; remission defined as decrease of depression scores below cut-off for the scale

Conditions Studied

Interventions

  • OTHER Combination use of MBCT and IV Ketamine

Study Locations (1)

Ohio

  • Harding Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2022-03-30
Est. Completion 2026-11-30
Phase Phase 4
Ohio State University

552 total trials

What the registry record for NCT05950711 still lists

NCT05950711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Combination use of MBCT and IV Ketamine is the first listed.

NCT05950711 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05950711 about?

NCT05950711 is a clinical study titled "Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study". The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.

What is the current status of trial NCT05950711?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2022-03-30. Estimated completion is 2026-11-30.

What conditions does trial NCT05950711 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT05950711?

The interventions under investigation include: Combination use of MBCT and IV Ketamine (OTHER).

Who is sponsoring clinical trial NCT05950711?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05950711 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05950711's enrollment target sits among peer trials

21 240th of 282 higher than 41 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05950711, the US trial registry maintained by the National Library of Medicine. NCT05950711 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.